Ben Bergo, CEO of Visus Therapeutics, gives a company update on the company's presented phase 2 data, and what's next in the pipeline.
"We look forward to providing further updates through this year and into next year with data read outs to file in the middle of 2023."
Last year, Visus Therapeutics completed VIVID, the company’s Phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia.
At this year's 2022 ASCRS meeting in Washington, D.C., Ben Bergo, CEO of Visus, gave an update on that data and the next steps in the pipeline.
The company is in two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL™ PF. BRIO-I and BRIO-II are double-masked, randomized, multi-center, safety and efficacy studies expected to enroll emmetropic phakic and pseudophakic presbyopic patients (approximately 170 and 500 respectively).